Evommune share price today

Evommune, Inc.'s share price was $6.04 at the close on 4 November 2026. That is 65.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between $5 and $32, and at that close it sat 4% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 26 weeks running.

Over the last 1 year the share price moved −67% while the S&P 500 moved +14%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 8 May 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Evommune, Inc. pays no dividend. In the last 5 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Evommune is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Evommune, Inc. posted a net loss of $28.3 M in the Dec 2025 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $68.9 M. That loss is 217.5% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier lost $2.8 M.

Read this profit with care: at −$28.3 M it is bigger than the quarter's whole revenue of $13.0 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −228.6% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings.

Evommune, Inc. reported $13.0 M of revenue in the Dec 2025 quarter, +85.7% on the same quarter a year earlier. Over 2 years it has grown 61.2% a year on average. The last full year, FY25, came in at $13.0 M.

Revenue is everything the company billed its customers in the period.

Recent pace: the last four quarters grew +14.3% on average, against 61.2% a year over the longer run, so this year is growing slower than its own long-run rate.

Evommune, Inc. has almost no sales yet: FY25 revenue was $13.0 M. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow.

Evommune, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $76.4 M of cash, against −$68.9 M of profit. After $235 K of spending on assets, free cash was −$76.7 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Evommune, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $441 K on assets over the last 3 years. Averaged over those years that is 1.1% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $441 K over the last 3 years.

In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.

Evommune, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Evommune, Inc. at 16.9× its FY25 revenue of $13.0 M. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Evommune, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Evommune, Inc. earned a ROE of −34% in FY25. That is up from a low of −144% in FY24. We cannot compare its return on capital used with its cost of capital from the data we have.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Evommune, Inc. has total debt of $8.6 M against shareholder equity of $278 M as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.02 in FY23 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

17.8% of Evommune, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 4.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Evommune, Inc., the Z-score is 16.62. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 16.62 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: Evommune, Inc. is not among the largest members shown in this industry comparison for Biotechnology.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Evommune is the 188th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Camp4 Therapeutics Corporation, Vanda Pharmaceuticals Inc. and AC Immune SA. Just below it: InflaRx N.V., Protalix BioTherapeutics, Inc. and Sol-Gel Technologies.

Biotechnology companies close in size

185. Camp4 Therapeutics Corporation $235 million
186. Vanda Pharmaceuticals Inc. $235 million
187. AC Immune SA $228 million
188. Evommune, Inc. $219 million
189. InflaRx N.V. $218 million
190. Protalix BioTherapeutics, Inc. $217 million
191. Sol-Gel Technologies Ltd. $216 million

All 211 Biotechnology companies, largest first

Companies close in size in other industries

3336. Clearwater Paper Corporation $216 million · Paper & Paper Products
3337. MaxsMaking Inc. $216 million · Conglomerates
3338. Evommune, Inc. $216 million
3339. Modiv Industrial, Inc. $215 million · REIT - Industrial
3340. Keros Therapeutics, Inc. $215 million · Biotechnology

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.